Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

Bio-Rad projects 2025 currency-neutral revenue growth of 1.5%-3.5%, excluding contributions from acquisitions. Diagnostics revenue is expected to grow between 2%-3%, while Life Science revenue is ...

"Our AI-powered platform is designed with the goal of transforming the IPO process by making it more efficient and accessible," said Edward C. Lee, CEO of Hestia Insight Inc. Mr. Lee continued, "This ...

South San Francisco has seen leasing and activity in its life sciences real estate market decrease despite a bevy of new ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...

DetraPel, Inc., a clean-tech advanced materials company, will relocate its headquarters and advanced manufacturing operations ...